Introduction
For infectious diseases that progress through a long infectious period, infectivity or infectiousness can vary greatly in time. The progression of a typical HIV infection can take 8-10 years before the clinical syndrome (AIDS) occurs, and the progression goes through several distinct stages, marked by drastically different CD4 + T-cell counts and viral RNA levels. HIV-infected individuals are highly infectious in the first few weeks after infection, then remain in an asymptotic stage of low infectiousness for many years, and become gradually more infectious as their immune system becomes compromised and they progress to AIDS. With antiretroviral drug treatment such as highly active antiretroviral therapy (HARRT), progression of HIV infection can be reverted so that a patient may ameliorate to higher CD4 + counts. Although antiretoviral therapies have greatly improved the survival rates of HIV patients, there is a concern that ameliorated patients may resume to be active in sexual or drug activities while being infectious, especially after an incomplete course of treatment. Such patients may have a much greater degree of infectivity because of risky behaviours and pose a greater threat to the general public. To fully evaluate the effectiveness of the antiretroviral therapies in the global war against HIV/AIDS, it is important to investigate the effects of amelioration on the population dynamics of the HIV transmission.
Staged-progression (SP) models have been formulated in the literature to investigate variability of infectivity during the progression of HIV infection [1, 4, 6, 8, 9, 11, 12, 18, 19, 20, 21] . In [11] , SP models using ordinary differential equations were derived. In [4] , SP models with general distribution functions were formulated, and the models are described by systems of differentialintegral equations. In [20] , amelioration was first incorporated into an SP model for HIV/AIDS with standard incidence and exponential recruitment. The basic reproduction number in the presence of amelioration was derived in [20] , and global analysis was carried out for the special case of three infectious stages. In [6] , effects of vaccine and amelioration on the progression of HIV were investigated using an SP model.
In this paper, we consider a general n-stage SP model that incorporates disease amelioration, with constant recruitment and density-dependent incidence. Our goals are to establish the global dynamics of the general n-stage model and to investigate the effects of amelioration on the global dynamics. Our results show that amelioration does not alter the qualitative behaviours of the SP model; its impacts are quantitative and achieved by changing the basic reproduction number. More specifically, we prove that, for a general class of density-dependent incidence forms, the dynamics of the model are completely determined by the basic reproduction number R 0 : if R 0 ≤ 1, the disease-free equilibrium P 0 is globally asymptotically stable; if R 0 > 1, then P 0 is unstable and a unique endemic equilibrium exists. For the case of bilinear incidence, we established the global stability of the endemic equilibrium when R 0 > 1. A similar threshold result has been established for an SP model without amelioration in [7] . Our global stability result also generalizes those in [20] .
With regard to the effects of amelioration on the basic reproduction number R 0 , our results show that introducing amelioration at stage k may change R 0 in both directions; whether it increases or decreases R 0 is determined by a quantity,
where R 0,k represents the average number of secondary infections produced by a single infective from stage k and onwards, when amelioration is not present (see Section 5) . This direct relation allows us to conclude that amelioration tends to increase R 0 in the following situations: (1) if the overall death rates are small; (2) if the amelioration is from a stage of high fatality rate to one with a much smaller fatality rate; and (3) if amelioration is from a stage of low infectivity to one with much higher infectivity. These findings have important implications on the HIV-infection dynamics. Since amelioration due to antiretroviral therapies usually comes with a reduction in fatality rates in HIV patients, if it is also accompanied by higher average infectivity because of risky behaviours, then the overall impact on the population level of antiretroviral therapies can be a net increase of the basic reproduction number, making the disease control in the whole population more difficult to achieve. Thus, it is crucial that antiretroviral therapies be administered with an education campaign to increase the awareness on danger of risky behaviours.
In the next section, we derive our model and present some preliminary analysis. Existence and uniqueness of the endemic equilibrium when R 0 > 1 are proved in Section 3. Global stability of the disease-free equilibrium is given in Section 4. Impacts of amelioration on the basic reproduction number R 0 are investigated in Section 5. In Section 6, we prove the global stability of the endemic equilibrium for the case of bilinear incidence using a global Lyapunov function. We end the paper with a brief summary in Section 6. 
An SP model with amelioration
To formulate an n-stage model with both disease progression and amelioration, the total host population is partitioned into the following compartments: the susceptible compartment S, the infectious compartment I i for individuals in the ith stage, where i = 1, 2, . . . , n, and the removed compartment R for individuals in the terminal stage of the disease who are removed from the infection process. For 1 ≤ i ≤ n − 1, let δ i denote the mean progression rate from the ith stage to the (i + 1)th stage, γ i+1 the mean amelioration rate from the (i + 1)th stage to the ith stage, and δ n the mean progression rate from the nth stage to the terminal stage of the disease. It is also assumed that there is no recovery from the disease, and thus the only exit from the compartment R is death. Let λ i ≥ 0 be the transmission coefficient for the infection of a susceptible individual by an individual in the compartment I i . Then the total incidence is given by n i=1 λ i I i Sf (N ) , where N = S + I 1 + · · · + I n is the total number of individuals who are active in the infection process. Here, we assume that the density dependence of the incidence is described by a function f (N), which will be specified later. A function class of special interest is f (N) = N −α , 0 ≤ α ≤ 1, as the resulting incidence term includes two of the most common forms: the standard incidence (α = 1) and the bilinear incidence (α = 0). The mean death rate for compartment S is d 0 , for the compartment I i is d i , which may include death due to infection, and for compartment R is d R . We assume the inflow of susceptibles is a constant . The population transfer among compartments are schematically depicted in the transfer diagram in Figure 1 . All parameters in the model are assumed to be non-negative. We remark that if λ i = 0 for some i, then the compartment I i will be regarded as a latent compartment. Thus, our model includes, as a special case, models of SE 1 · · · E m I 1 · · · I n R type, for any finite m and n. When all the amelioration rates are zero, our model reduces to the staged progression model in [7] .
Based on our assumptions and the transfer diagram, the following system of differential equations can be derived for the n-stage model,
and R = δ n I n − d R R. The incidence term is λ S, where the force of infection,
is density-dependent. We assume that the function f (N) is C 1 for N > 0 and satisfies the following assumptions. 
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The assumptions that f (N) > 0 and f (N ) ≤ 0 are biologically motivated; as the total population N increases, the probability of a contact with a susceptible decreases, and thus the force of infection is expected to be a decreasing function of N . The third condition is imposed to ensure uniqueness of the endemic equilibrium when R 0 > 1 and global stability of the disease-free equilibrium when R 0 ≤ 1. These conditions imply that Nf (N ) is monotonically non-decreasing,
, including the standard incidence (α = 1) and the bilinear incidence (α = 0).
Adding the Equations in (1), we obtain
Here, we assume that d > 0 so that the total active population N remains bounded. Similarly, from the first part of Equation (1), we obtain S ≤ − d 0 S, and thus lim t→∞ sup
+ is contained in the bounded closed set,
It can be verified that is positively invariant.
Existence and uniqueness of the endemic equilibrium
An equilibrium (S, I 1 , . . . , I n ) of Equation (1) satisfies,
The disease-free equilibrium
Then −A is an M-matrix. As a consequence, −A −1 exists and is non-negative. Furthermore, there exists α > 0 such that −A −1 x ≥ α x for x ≥ 0 (see Appendix). It follows that
and that
where the superscript t denotes the transposition. The basic reproduction number of equation (1) is
It can be derived using the method of next generation matrix as given in [16] . In Section 4, we derive expressions of R 0 in terms of model parameter for some special cases. Proof It suffices to prove that the unique endemic equilibrium P * exists if and only if R 0 > 1. To show this, we write the last n equations of Equation (3) in the form,
Multiplying the row vector (λ 1 , . . . , λ n ) with Equation (8) and using Equations (2) and (5), we obtain,
Similarly, multiplying row vector (1, . . . , 1) with Equation (8), and applying Equation (2), we have,
where p > 0 is defined in Equation (6) . From the first equation of Equation (3), we get
, and thus
Substituting Equation (11) into Equation (9), we obtain the following equation for endemic equilibria
We will show that Equation (12) has a unique positive solution in the interval (0, /d 0 ) when R 0 > 1 using the standard graphical method. Let,
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Then g(0) = 0, and g(
where
is strictly monotonically increasing, and its graph has at most one intersection with the line y = 1/β. Such an intersection exists for 
Note that c k ≥ 0, k = 1, . . . , n, since −A −1 is non-negative. In particular,
Rewriting the last n equations in Equation (1) as (I 1 , . . . , I n ) t = (λS, 0, . . . , 0) t + A (I 1 , . . . , I n ) t , and using assumption (H) and the fact that Nf (N ) is non-decreasing, we obtain that, along a solution of Equation (1),
It can be verified that the largest compact invariant subset of the set G = { (S, I 1 , . . . , I n ) ∈ : L = 0} is the singleton {P 0 }. Therefore, all solutions in converge to P 0 , by the LaSalle Invariance Principle [16] . The global attractivity of P 0 and the Lyapunov function L imply that P 0 is also locally stable, since otherwise P 0 will have a homoclinic orbit that is entirely contained in G, contradicting that the largest compact invariant set in G is {P 0 }. This establishes the global stability of P 0 when R 0 ≤ 1. sufficiently close to P 0 move away from P 0 , except those on the invariant S-axis, along which solutions converge to P 0 . Therefore, this implies that P 0 is unstable. The maximal invariant set on the boundary of R n+1 + is the singleton {P 0 } and is isolated. By a uniform persistence result (Theorem 4.3) in [5] , the instability of P 0 implies that system (1) is uniformly persistent [3] . This completes the proof of Theorem 4.1.
Impacts of amelioration on the basic reproduction number
Theorems 3.1 and 4.1 establish R 0 as a sharp threshold parameter. If R 0 ≤ 1, the disease dies out irrespective of the initial number of cases. If R 0 > 1, then the disease persists in the feasible region, and there is a unique endemic equilibrium.
For the special case of bilinear incidence (f (N) = 1) and when all death rates are the same as , namely, d i = , i = 1, . . . , n, the R 0 in Equation (7) gives the basic reproduction number in [20] for the system of fractional variables. For the special case when there is no amelioration, explicit expressions of β in Equation (5) and R 0 in Equation (7) can be derived. In this case, the matrix A in Equation (4) is lower triangular, and
where c ij 's are determined by the following iterative relations
Therefore, when γ i = 0, i = 1, . . . , n,
, then R 0 gives the basic reproduction number for the standard incidence as in [11, 20, 22] , while if α = 0, R 0 gives the basic reproduction number for the bilinear incidence. We note that the basic reproduction number for a class of finite-stage SP models with a general distribution function for the infectious periods was derived in [4] .
To investigate the impacts of amelioration on the basic reproduction number, we introduce, for k = 1, . . . , n,
which represents the average number of secondary infections produced by an infective from the kth stage of the disease progression onwards when no amelioration is present. If k = 1, then R 0,1 gives the basic reproduction number R 0 in Equation (14) . The following relation is immediate from Equation (15) .
Recall that γ k is the rate of amelioration from stage k to stage k − 1. Let γ = (γ 2 , γ 3 , . . . , γ n ).
THEOREM 5.1 Let R 0,k be defined in Equation (15) . Then
Proof Using relation (5) and expression (7) for R 0 and differentiating the identity AA −1 = I with respect to γ k , we obtain,
Using the definition of A in Equation (4) to calculate the partial derivative ∂A/∂γ k in the relation above, then setting γ = 0 and using the expression for −A −1 in Equation (13), we obtain relation (17).
Intuitively, Theorem 5.1 describes the effects on the basic reproduction number in a forward progression model when amelioration is introduced at the kth stage of the disease. In this case, when an infective ameliorates from stage k to stage k − 1, the average number of secondary infections is increased by R 0,(k−1) and is decreased by R 0,k , with the net gain k = R 0,(k−1) − R 0,k . Therefore, amelioration at stage k increases R 0 if k > 0, and it decreases R 0 if k < 0.
Several conclusions can be drawn based on Theorem 5.1. We first observe from Equation (15) that if the overall death rate d k−1 , including the disease-caused death and natural death, is small, then
and amelioration at stage k increases R 0 . We thus have the following conclusions.
(1) Amelioration tends to increase R 0 for non-fatal diseases. This is also the case if amelioration is from a stage with high fatality rate to a stage with much lower fatality rate. We also observe from Equation (16) 
Observation (2) has important implications for antiviral therapy of HIV/AIDS. It is known that HIV infection has several distinctive stages according to the level of CD4
+ count. HIVinfected individuals are highly infectious in the first few weeks after infection, then remain in an asymptotic stage of low infectiousness for many years, and become gradually more infectious as they progress to AIDS. However, HIV-positive patients may be sexually much more active during the long asymptotic stage than during the later stage when they become more aware of the infection or when they are more limited by their physical conditions. As a consequence, the transmission coefficient λ k may be greater during the asymptotic phase because of more sexual contacts or more needle sharing, the so-called risky behaviours, than during the later stages. If antiviral therapies only lead to partial amelioration to the asymptotic phase, then a net effect can be an increase of the basic reproduction number R 0 , making the infection control at the population level more difficult to achieve. It is important that antiviral therapies are administered with an education campaign to reduce risky behaviours.
If a treatment measure only results in partial amelioration, then it is most effective at a population level if applied at the disease stage with the highest infectivity, namely the largest transmission coefficient, λ k . We thus have the following conclusion. 
The proof of Theorem 6.1 utilizes a global Lyapunov function
, and constants B i are defined inductively as follows:
It follows from these definitions that B i satisfies a linear system,
Solving this system, we obtain,
where matrix A is given in Equation (4). We first establish the following properties of B i . (20) , satisfy the following relations.
PROPOSITION 6.2 The constants B i , as defined in Equation
(a) B k (d k + δ k + γ k )I * k = n i=k λ i I * i S * + B k−1 γ k I * k + B k γ k+1 I * k+1 , 2 ≤ k ≤ n − 1. (b) B i δ i−1 I * i−1 = n k=i λ k I * k S * + B i−1 γ i I * i , 2 ≤ i ≤ n − 1.
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Proof To see the relations in Equation (1), we multiply the ith equation in Equation (21) by I * i and obtain
For i = 2, . . . , n, multiplying the ith equation in (18) by B i , we get,
For 2 ≤ k ≤ n − 1, adding the last (n − k + 1) equations in (22), we obtain,
Similarly, adding the last (n − k) equations in (23), we arrive at
The identities in (a) follow from relations (24) and (25).
To derive the relations in (b), we equate the left-hand sides of the ith equations in Equations (22) and (23), for i = 1, . . . , n, and obtain
From the first identity in Equation (26) 
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Continuing the proof of Theorem 6.1, we compute the derivative of the Lyapunov function W and obtain,
Using system (1) we have,
In the second step of the above derivation, we substituted by the right-hand side of the first part of Equation (18) . Similarly, using Equations (1) and (18), we obtain,
For i = 2, . . . , n − 1, using Equation (1), we have,
and
Substituting Equations (29)-(33) into Equation (28), using B 1 = 1 and rearranging terms, we obtain,
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From relations (21) , we see that W 1 ≡ 0 for all I 1 , I 2 , . . . , I n . Substituting the first equilibrium equation in (23) into W 2 , we have,
Substituting the identities in (a) of Proposition 6.2 into the above relation, we obtain, 
Substituting Equation (36) into W 3 , we get, Theorems 4.1 and 6.1 that the global dynamics of the model is completely determined by the basic reproduction number R 0 : if R 0 ≤ 1, then the disease-free equilibrium is globally asymptotically stable and the disease dies out; if R 0 > 1, then the unique endemic equilibrium P * is globally asymptotically stable and the disease persists at the level of P * . Our global stability result for P * generalizes earlier results in [7, 20] . The proof utilizes a global Lyapunov function motivated by the work in [13] [14] [15] . We have shown that introducing amelioration at stage k of the disease progression indeed may increase the basic reproduction number, and hence may have a negative effect on the disease control in the population. We have introduced in Equation (15) a quantity R 0,k that measures the average number of secondary infections produced by an infective from the kth stage of the disease progression onwards when no amelioration is present. We show in Theorem 5.1 that the introduction of amelioration at stage k will increase R 0 if and only if R 0,(k−1) > R 0,k . Based on this result and relation (16), we conclude that amelioration tends to increase R 0 if it is into a stage that has either (1) a much lower fatality rate, or (2) much higher infectivity, or (3) a much longer duration. In the case of HIV, this implies that if risky behaviours result in higher infectivity on average after antiretroviral therapies, then the basic reproduction number may increase.
